Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, Ji Hoon Na, Hyun Sik Kim, Hyoun A Kim, Hye Won Kang, Soon Koo Baik, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Moon Young Kim
Clin Mol Hepatol. 2014;20(4):376-383.   Published online 2014 Dec 24     DOI: https://doi.org/10.3350/cmh.2014.20.4.376
Citations to this article as recorded by Crossref logo
Portal Hypertension and Related Complications: Diagnosis and Management
Douglas A. Simonetto, Mengfei Liu, Patrick S. Kamath
Mayo Clinic Proceedings.2019; 94(4): 714.     CrossRef
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Paul Manka, Amos Zeller, Wing-Kin Syn
Drugs.2019; 79(9): 903.     CrossRef
Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon
Seong Hee Kang, Moon Young Kim, Soon Koo Baik
Hepatology International.2018; 12(S1): 112.     CrossRef
Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials
Huijing Yao, Chunqing Zhang
Irish Journal of Medical Science (1971 -).2018; 187(4): 925.     CrossRef
Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik
The Korean Journal of Internal Medicine.2018; 33(3): 453.     CrossRef
Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score
Seong Hee Kang, Woo Kyoung Jeong, Soon Koo Baik, Seung Hwan Cha, Moon Young Kim
Journal of Cachexia, Sarcopenia and Muscle.2018; 9(5): 860.     CrossRef
Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis
Gaeun Kim, Kwang Yong Shim, Soon Koo Baik
Gut and Liver.2017; 11(1): 93.     CrossRef
Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
Choon OK Kim, Sangil Jeon, Seunghoon Han, Taegon Hong, Min Soo Park, Young-Ran Yoon, Dong-Seok Yim
Translational and Clinical Pharmacology.2017; 25(1): 43.     CrossRef
Novel treatment options for portal hypertension
Philipp Schwabl, Wim Laleman
Gastroenterology Report.2017; 5(2): 90.     CrossRef
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon
Gut and Liver.2017; 11(5): 702.     CrossRef
Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review
Gaeun Kim, Juyoung Kim, Yoo Li Lim, Moon Young Kim, Soon Koo Baik
Hepatology International.2016; 10(5): 819.     CrossRef
Emerging therapies for portal hypertension in cirrhosis
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch
Expert Opinion on Emerging Drugs.2016; 21(2): 167.     CrossRef
Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
Hyun Woong Lee
Clinical and Molecular Hepatology.2014; 20(4): 345.     CrossRef